MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Income Statement
NASDAQ:MLTX - Nasdaq - KY61559X1045 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Minority Interest Expense | 2.62M | 2.31M | 8.07M | 14.53M | N/A | |||
| Operating Expenses | 170.76M | 143.09M | 54.12M | 65.06M | 53.58M | |||
| Research and Development | 136.22M | 112.77M | 31.80M | 42.05M | 35.53M | |||
| Selling, General, and Administrative Expenses | 34.54M | 30.32M | 22.32M | 23.01M | 18.04M | |||
| Operating Income | -170.76M | -143.09M | -54.12M | -65.06M | -53.58M | |||
| Interest Income/Expense | N/A | N/A | N/A | N/A | 27.69K | |||
| Other Income/Expense | 23.31M | 22.13M | 10.14M | 590.00K | -60.00K | |||
| Income Before Taxes | -147.46M | -120.96M | -43.98M | -64.47M | -53.64M | |||
| Income Tax | 364.90K | 282.20K | 94.40K | 40.00K | 0.00 | |||
| Net Income | -145.21M | -118.94M | -36.01M | -49.97M | -53.64M | |||
| EBITDA | -169.02M | -141.71M | -54.11M | -65.05M | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.30 | -1.89 | -0.73 | -1.70 | -1.45 | |||
| Non GAAP EPS | -2.30 | -1.89 | -0.76 | N/A | N/A | |||
| Statistics | ||||||||
All data in USD